Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22185786 | 0.89 | LPL (0.40) | LPLLIPGFFAR1F2F11 | |
| SCHEMBL29506948 | 0.86 | AR (0.40) | LPLLIPGFFAR1F2F11 | |
| SCHEMBL406138 | 0.86 | AR (0.40) | LPLLIPGFFAR1F2F11 | |
| SCHEMBL30523101 | 0.84 | FFAR1 (0.40) | LPLLIPGFFAR1DGAT1HIF1A | |
| SCHEMBL16008825 | 0.84 | FFAR1 (0.40) | LPLLIPGFFAR1DGAT1HIF1A | |
| SCHEMBL23597018 | 0.82 | FFAR1 (0.44) | LPLLIPGFFAR1F2F11 | |
| SCHEMBL22977685 | 0.79 | DGAT1 (0.38) | LPLLIPGFFAR1DGAT1AAK1 | |
| SCHEMBL22289520 | 0.78 | FFAR1 (0.42) | LPLLIPGFFAR1F11DGAT1 | |
| SCHEMBL12989288 | 0.78 | FFAR1 (0.36) | LPLLIPGFFAR1DGAT1EGFR | |
| SCHEMBL13195651 | 0.77 | CA1 (0.38) | LPLLIPGFFAR1DGAT1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053342-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053342-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, SLC5A11, CYP51A1 | LPL 4775/4885LIPG 4773/4885FFAR1 1839/4885 |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | PIK3CA, AKT3, GSK3B | LPL 1332/4885LIPG 496/4885FFAR1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.